Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CYCLOPHOSPHAMIDE

All products: general benefit

Other products in the same Health Canada class (L01A, L01AA) — coverage varies; not interchangeable

  • Chlorambucil (Leukeran): general benefit
  • Melphalan (Alkeran): general benefit
  • Busulfan (Myleran): general benefit
  • Lomustine ccnu (Gleostine): general benefit, Listing status unconfirmed
  • Temozolomide (Temodal): general benefit

Procytox · DIN 02241796 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Procytox · DIN 02241796 Manufacturer: Baxter Corporation; listing date 2005-05-25 Health Canada: Marketed since 2003-09-09 · brand PROCYTOX · ATC L01AA01 CYCLOPHOSPHAMIDE · form Tablet · route Oral · ingredients CYCLOPHOSPHAMIDE 50 MG · company Baxter corporation · schedule Prescription
Check this DIN again · Health Canada product record

Procytox: Formulary list price $0.4773/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65461 · Verify on the e-Formulary ↗ (DIN 02241796)

Source record
DIN 02241796: Procytox Raw flags: sec3=Y Item: 100000007; group id 151; item number 0256; lccId None; manufacturer id BAX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.4773; ministry $0.4773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65461
Interchangeable products
Cytoxan · DIN 00344885 · not recorded
Shortage status: resolved shortage (ended 2025-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241796
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

MELPHALAN

· 1 products · General benefit · strengths: 2mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

LOMUSTINE (CCNU)

· 5 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (1) · strengths: 10mg, 40mg, 100mg · Cap

TEMOZOLOMIDE

· 20 products · General benefit · strengths: 5mg, 20mg, 100mg, 140mg, 250mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE PROCYTOX (Cyclophosphamide), used alone or as a component of combination therapy is indicated for: A: Frequently responsive myeloproliferative and lymphoproliferative disorders 1. Malignant lymphomas (See also DOSAGE AND ADMINISTRATION) a) Hodgkin's disease [Cotswold stages II & III (massive mediastinal disease) and IIIA1,2 - IV E] Non-Hodgkin's lymphomas (Working Formulation. Low Grade A,B,C; Intermediate Grade D,E,F,G; High Grade H,I,J) b) Follicular lymphoma (B,C,D) c) Lymphocytic lymphoma (A,B,E; mixed histiocytic, C,F) ** Note: Type A, small diffuse and well differentiated malignant lymphocytic lymphoma is consistent with chronic lymphocytic leukemia, to be considered a heterogenous group of chronic B-cell disorders. d) Diffuse histiocytic lymphoma (G,H) e) Lymphoblastic lymphoma (I) f) Burkitt's lymphoma (J) PROCYTOX (Cyclophosphamide) … https://pdf.hres.ca/dpd_pm/00017604.PDF PM date: not printed or not captured Source product: PROCYTOX; DIN 02241795; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.